EyePoint Pharmaceuticals (EYPT) Liabilities and Shareholders Equity: 2011-2019
Historic Liabilities and Shareholders Equity for EyePoint Pharmaceuticals (EYPT) over the last 8 years, with Mar 2019 value amounting to $81.9 million.
- EyePoint Pharmaceuticals' Liabilities and Shareholders Equity rose 63.19% to $81.9 million in Q1 2019 from the same period last year, while for Mar 2019 it was $320.5 million, marking a year-over-year increase of 232.66%. This contributed to the annual value of $71.7 million for FY2018, which is 283.73% up from last year.
- Latest data reveals that EyePoint Pharmaceuticals reported Liabilities and Shareholders Equity of $81.9 million as of Q1 2019, which was up 4.72% from $78.2 million recorded in Q4 2018.
- EyePoint Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $88.9 million during Q3 2018, with a 5-year trough of $13.3 million in Q3 2017.
- Over the past 3 years, EyePoint Pharmaceuticals' median Liabilities and Shareholders Equity value was $50.2 million (recorded in 2018), while the average stood at $48.3 million.
- In the last 5 years, EyePoint Pharmaceuticals' Liabilities and Shareholders Equity plummeted by 51.60% in 2017 and then skyrocketed by 566.73% in 2018.
- Quarterly analysis of 5 years shows EyePoint Pharmaceuticals' Liabilities and Shareholders Equity stood at $23.9 million in 2015, then fell by 17.55% to $19.7 million in 2016, then decreased by 28.10% to $14.2 million in 2017, then spiked by 450.60% to $78.2 million in 2018, then spiked by 63.19% to $81.9 million in 2019.
- Its Liabilities and Shareholders Equity was $81.9 million in Q1 2019, compared to $78.2 million in Q4 2018 and $88.9 million in Q3 2018.